Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine:
1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their
condition more often or recover faster than children who do not receive drotrecogin alfa
(activated).
2. Whether drotrecogin alfa (activated) minimizes long term disabilities associated with
severe sepsis.
3. The side effects that might be associated with drotrecogin alfa (activated)
administration to children with severe sepsis.